PRUNE2 mutation status did not correlate with clinical parameters such as severity of disease (Ca-ion or PTH levels at diagnosis), tumor size, or parafibromin staining on immunohistochemistry, neither by looking at all rare prune mutations in our cohort nor by separately analyzing the variants considered damaging. This evidence concerns the gene PRUNE2 and neoplasm.